21 January 2015

BRADY CENTENNIAL

The Brady Urological Institute, given through the generosity of the James Buchanan Brady, opened January 21,1915

1897-1941

Hugh H. Young

Young performed the first perineal prostatectomy at the Johns Hopkins Hospital, 1927.

1946-1974

William W. Scott

During his tenure, Scott gave 15 named lectures and participated in some 25 visiting professorships.

1974-2004

Patrick C. Walsh

2004-present

Alan W. Partin

Dr. Partin is best known for developing The Partin Tables

1964-1969

H.G.Williams-Ashman
Read More

1947-1974

Charles Tesar
Read More

1974-2004

Donald S. Coffey
Read More

2013

Kenneth J. Pienta
Read More

BRADY 100 Years

Brady 100 years

A history of the James Buchanan Bray Urological Institute at the Johns Hopkins Medicine

 


A Guide to the papers of Hugh Hampton Young in the Alan Mason Chesney Archives

by Marjorie Winslow Kehoe, Nancy McCall and Lisa A. Mix


Autobiography


Over 100 drawings by William Didusch and three color prints

Harcourt, Brace and Company , New York


Autobiography


My story is based on actual events. However, following the current autobiographical custom adopted by politicians in their memoirs, I have adjusted the truth wherever it might reflect unfavorably on myself

William Wallance Scott, Sr., MD


 


The story of UROLOGY AT HOPKINS is found in bits and pieces in books, journals, letters, reports and the memories of people who have devoted part of their lives to urology.



1971

Androgenic Control of Nucleic Acid and Protein Synthesis in Male Accessory Genital Organs

1971

Effects of Polyinosinic Acid and Polycytidylic Acid on the Deoxyribonucleic Acid Template Activity of Isolated Nuclei and Soluble Chromatin from Rat Liver

1972

Effects of Polyinosinic Acid and Polycytidylic Acid on the Deoxyribonucleic Acid Template Activity of Isolated Nuclei and Soluble Chromatin from Rat Liver

1973

Bladder exstrophy: Vesicoplasty or urinary diversion?

1974

Permanent urinary diversion in childhood

1975

Nuclear Protein Matrix: Association with Newly Synthesized DNA

1976

The Induction of Prostatic Hypertrophy in the Dog with Androstanediol

1978

Characterization of the Binding of a Potent Synthetic Androgen, Methyltrienolone, to Human Tissues

1979

Comparison of spontaneous and experimentally induced canine prostatic hyperplasia

1980

Supercoiled loops and eucaryotic DNA replication

1980

A fixed site of DNA replication in eucaryotic cells

1981

Pathological factors that influence prognosis in stage A prostatic cancer: the influence of extent versus grade

Genetic Instability Coupled to Clonal Selection as a Mechanism for Tumor Progression in the Dunning R-3327 Rat Prostatic Adenocarcinoma System

1982

Impotence following radical prostatectomy: insight into etiology and prevention

1983

Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations

1986

Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers.

1986

Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells

1988

Activation of programmed cell death in the rat ventral prostate after castration

1989

Etiology and disease process of benign prostatic hyperplasia

1990

Allelic loss of chromosomes 16q and 10q in human prostate cancer

Programmed Cell Death during Regression of PC-82 Human Prostate Cancer following Androgen Ablation

1992

Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease

Nitric oxide: a physiologic mediator of penile erection.

Mendelian inheritance of familial prostate cancer

The Effect of Finasteride in Men with Benign Prostatic Hyperplasia

1994

Pathologic and Clinical Findings to Predict Tumor Extent of Nonpalpable(Stage T1 c) Prostate Cancer

The Role of Calcium, pH, and Cell Proliferation in the Programmed (Apoptotic) Death of Androgen-independent Prostatic Cancer Cells Induced by Thapsigargin

Cytidine methylation of regulatory sequences near the a-class glutathione S-transferase gene accompanies human prostatic carcinogenesis

1995

KAI1, a metastasis suppressor gene for prostate cancer on human chromosome

Laparoscopic Live Donor Nephrectomy

1996

Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search

Telomerase Activity: A Prevalent Marker of Malignant Human Prostate Tissue

1997

Prostate Attenuated Replication Competent Adenovirus (ARCA)CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells

Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells

Specific and Efficient Peptide Substrates for Assaying the Proteolytic Activity of Prostate-specific Antigen

Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells

1998

Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease

ANALYSIS OF PERCENT FREE PROSTATE-SPECIFIC ANTIGEN (PSA) FOR PROSTATE CANCER DETECTION: INFLUENCE OF TOTAL PSA, PROSTATE VOLUME, AND AGE

1999

Natural History of Progression After PSA Elevation Following Radical Prostatectomy

Proliferative Inflammatory Atrophy of the Prostate Implications for Prostatic Carcinogenesis

Induction of Immunity to Prostate Cancer Antigens: Results of a Clinical Trial of Vaccination with Irradiated Autologous Prostate Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-stimulating Factor Using ex Vivo Gene Transfer

Overexpression of Hypoxia-inducible Factor 1α in Common Human Cancers and Their Metastases

2000

Comparative Efficiency of Prostate-Specific Antigen Screening Strategies for Prostate Cancer Detection

2001

Human Prostate Cancer and Benign Prostatic Hyperplasia: Molecular Dissection by Gene Expression Profiling

A Phase I Trial of CV706, a Replication-competent, PSA Selective Oncolytic Adenovirus, for the Treatment of Locally Recurrent Prostate Cancer following Radiation Therapy

2002

α-Methylacyl-CoA Racemase: A New Molecular Marker for Prostate Cancer

Identification and Characterization of Nuclease-stabilized RNA Molecules That Bind Human Prostate Cancer Cells via the Prostate-specific Membrane Antigen

Telomere Shortening Is an Early Somatic DNA Alteration in Human Prostate Tumorigenesis

2003

Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer

2004

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2005

Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

The 2005 International Society of Urological Pathology(ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy

2006

Germ-Line Mutation of NKX3.1 Cosegregates with Hereditary Prostate Cancer and Alters the Homeodomain Structure and Function

2007

A New Type of Motor: Pneumatic Step Motor

2008

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

A Molecular Analysis of Prokaryotic and Viral DNA Sequences in ProstateTissue From Patients With Prostate Cancer Indicates the Presence of Multiple and Diverse Microorganisms

Prostate Cancer–Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy

Cumulative Association of Five Genetic Variants with Prostate Cancer

2009

Ligand-independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone Refractory Prostate Cancer

Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer

miR-21: An androgen receptor regulated microRNA which promotes hormone dependent and independent prostate cancer growth

Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer

2010

Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements

2011

PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

2012

Germline Mutations in HOXB13 and Prostate Cancer Risk

African American Men With Very Low–Risk Prostate Cancer Exhibit Adverse Oncologic Outcomes After Radical Prostatectomy: Should Active Surveillance Still Be an Option for Them?

2013

Tracking the clonal origin of lethal prostate cancer

1905

Conservative Perineal Prostatectomy

The Early Diagnosis and Radical Cure of Carcinome of the Prostate

1913

A New Procedure (PUNCH OPERATION) for small prostatic bars and contracture of the prostatic orifice

1917

The use of radium and the punch operation in desperate cases of enlarged prostate

1918

The employment of the high frequency current for the extraction of calculi incarcerated in the lower end of the ureter

1919

A new germicide for use in the genito-urinary tract: "mercurochrome-220"

1920

Observations on gun-shot wounds of the urethra

1921

Physiological and pharmacological studies of the prostate gland

1922

An operation for the cure of incontinence associated with espispadias

1923

The treatment of septicemia and local infections

1924

Secondary closure of tuberculous nephrectomy wounds

1925

Presentation of preoperative skin desinfectant - an alcohol- acetone-aqueous solution of mercurochrome

1926

Deep roentgen-ray therapy in the treatment of carcinoma of the bladder

1928

Vas ligation for the prevention of preoperative and post-operative epididymitis

1930

Medical Aspects of the treatment of benign prostatic hypertrophy

1931

A radical operation for the cure of cancer of the penis

1932

Carcinoma of the prostate, a clinical and pathological study

1934

Radiation Therapy of renal cortical neoplasms

1935

Bladder abnormalities due to injury of motor pathways in the nervous system

1937

The use of sulfanilamide in gonococcic infections

1938

Hypertension in unilateral renal disease

1939

Clinical experiments with androgens

1940

Stenosis of the ureteropelvic juncture: congenital and acquired

1941

Postoperative venous thrombosis and pulmonary embolism

1943

Carcinoma of the prostate

1944

The excretion of 07- ketosteroids in carcinoma of the prostate

1945

Treatment of bladder dysfunction after neurologic trauma

1946

Infiltrating carcinoma of the bladder: relation of depth of penetration of the bladder wall to dence of local extension and metastases

1947

Endocrine therapy in carcinoma of the prostate

1948

A new concept in the treatment of peynorie's diseases

1949

Xylocaine: a new topical anesthetic in urology

1950

Prostatic cancer

1951

Renal trauma: a study of 71 cases

1952

Infiltrating carcinoma of the bladder

1953

What makes the prostate grow

1954

Renal homotransplantation: I The effect of cortisone on the transplant; II The effect of the transplant on the host

1955

Operation for tumor of a solitary kidney

1956

Significance of the palpable prostatic nodule

1957

Steroid response to therapy in prostatic cancer

1958

The surgical treatment of carcinoma of the bladder

1959

Radical Prostatectomy for early cancer

1960

Carcinoma of the bladder: characteristic modes of local invasion

1961

Functional charactersitics of renovascular hypertension

1962

Hypophysectomy for disseminated prostatic cancer

1963

Radiographic evaluation of the bladder neck in childhood

1964

The effect of hypothermia upon respiration and anaerobic glycolysis of dog kidney

1965

Androgenic Control of Nucleic Acid and Protein Synthesis in Male Accessory Genital Organs

Director of Research
1964-1969

H.G. Williams-Ashman helped research flourish at the Brady Urological Institute. As the first research director, he established Brady’s international reputation as a scientific powerhouse.

The principal research advances made by Williams-Ashman and his coworkers over the five-year period from 1964 to 1969 were polyamine metabolism in the prostate gland and other mammalian organs; deoxyribonucleic acid synthesis in testis and prostate; hormonal regulation of protein synthesis; mechanisms of semen coagulation; and studies on male accessory genital gland metabolism, including fructose and nucleotide.
Director of Research
1947-1974

Charles Tesar ushered in a new era of scientific breakthroughs by designing and planning what a modern lab should look like.

During his time as the laboratory director, he trained and supported over 50 budding investigators. Additionally, he came to be known as a talented cartoonist, sharing his wonderful sense of humor with his colleagues.

Honors he was awarded during his long and fruitful career include a research fellowship at the Columbia University College of Physicians and Surgeons, a senior Fulbright Scholar Program grant for the Jules Bordet Institute in Belgium and a fellowship at the American Association for the Advancement of Science in Washington, D.C.
Director of Research
1970-2004

Donald Coffey was a gifted mentor and brilliant scientist who led research at the Brady Urological Institute for over three decades.

His storied legacy includes some of the field’s most significant discoveries, such as the nuclear matrix of cells.

But among his numerous achievements, the most important is that he attracted, inspired and trained countless students. "Today, when one looks at the leaders in urological research, every one of them has the imprint of Don Coffey, one way or another," says Alan Partin, director of the Brady Urological Institute.
The Donald S. Coffey Professor of Urology
Professor, Oncology, Pharmacology and Molecular Sciences

Dr. Kenneth J. Pienta is the Donald S. Coffey Professor of Urology and a professor of oncology and of pharmacology and molecular sciences at the Johns Hopkins University School of Medicine. He is a two-time American Cancer Society Clinical Research Professor Award recipient. He serves as the director of research for the Brady Urological Institute.